2003
DOI: 10.1615/jenvpathtoxoncol.v22.i3.40
|View full text |Cite
|
Sign up to set email alerts
|

Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 1)

Abstract: Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way healthcare workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequence… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2005
2005
2008
2008

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Similarly, the HIV titer is now routinely measured in AIDS patients to assess the response to drug therapy. In the near future, HIV viral genotyping will routinely be used to select the optimal drug therapy for AIDS patients [11,13], and patients may also be genotyped to optimize selection of HIV therapy [14]. These examples provide a few instances where pharmacogenomic data has been used to optimize treatment.…”
mentioning
confidence: 99%
“…Similarly, the HIV titer is now routinely measured in AIDS patients to assess the response to drug therapy. In the near future, HIV viral genotyping will routinely be used to select the optimal drug therapy for AIDS patients [11,13], and patients may also be genotyped to optimize selection of HIV therapy [14]. These examples provide a few instances where pharmacogenomic data has been used to optimize treatment.…”
mentioning
confidence: 99%